A planned interim efficacy analysis of the DREAMM-7 head-to-head phase III trial evaluating Blenrep (belantamab mafodotin) as a second-line treatment for relapsed or refractory multiple myeloma produced positive headline results.
To access this subscriber-only content please log in or subscribe.
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe